Luminopia Amblyopia Gains Hold One Year After Treatment

Real-world registry data presented at Academy 2026 shows children kept visual acuity improvements after stopping the therapy.

Updated on Nov. 16, 2026 in Asthma

Luminopia Amblyopia Gains Hold One Year After Treatment

Cleveland Clinic researchers presented real-world data on Luminopia treatment for amblyopia at Academy 2026 in Anaheim, Calif. Among 84 children who began the treatment at an average age of 7.2 years, best corrected visual acuity improved by a mean of 1.3 logMAR lines, and no serious adverse events were reported.

Why it matters

Amblyopia is a common cause of reduced vision in childhood, and the findings suggest that gains from Luminopia can persist after treatment ends, which bears on how long families may need to continue care. The data come from a registry of real-world use rather than a controlled trial, so they describe how the treatment performs outside a study setting.

The analysis covered 84 children averaging 8.3 months of use, with most (82%) having previously been treated for amblyopia for an average of 27 months. Follow-up after treatment is limited, and the subgroup of 27 children seen about 10 months later had one recurrence.

The players

Cleveland Clinic Cole Eye Institute

The Cleveland Clinic's eye institute is a major ophthalmology center that conducts clinical and research programs on eye and vision disorders.

Ann & Robert H. Lurie Children's Hospital of Chicago

Lurie Children's is a large pediatric hospital in Chicago affiliated with Northwestern University's Feinberg School of Medicine, known for its pediatric specialty care.

The details

Researchers at the Cleveland Clinic Cole Eye Institute analyzed data from the Luminopia PUPiL registry for children who used the treatment for amblyopia. Visual acuity was measured after treatment ended to test whether it worsened by one or more lines, and no serious adverse events were reported during the study.

Timeline

  1. Children began Luminopia at an average age of 7.2 years and used it for an average of 8.3 months.

  2. Visual acuity was tracked for an average of 6.7 months after treatment ended.

  3. A subgroup of 27 children was followed for an average of 10 months after treatment ended.

  4. The findings were presented at Academy 2026 in Anaheim, Calif.

Health Landscape

The findings extend the controlled-trial work of the PEDIG amblyopia studies to a digital therapy assessed through real-world use. Because the Luminopia data are observational, they add context to, rather than replace, the randomized evidence that shaped current amblyopia treatment.

Families of children with amblyopia may find that a digital therapy can be used at home and that gains reported in this registry held for months after stopping. Parents should discuss with an eye doctor whether a therapy like Luminopia fits a child's needs, since the data describe average outcomes rather than guaranteed results.

The takeaway

Gains from amblyopia treatment may last after therapy ends, but recurrence does occur, so periodic eye checks remain important. Parents should ask an eye care provider how long follow-up should continue for their child.

Further reading

For more on childhood eye and breathing conditions, explore the Asthma section of our health coverage.

Source note: This article includes information reported by Healio.